Title

Center for Research & Analytics (CENTRA)

The ASCO Center for Research and Analytics (CENTRA) serves as the hub of ASCO research activities to conduct, enable, and define standards for oncology research. CENTRA aims to make an assortment of ASCO-developed cancer data available to the oncology community for research purposes.

Mission

To conquer cancer by generating, integrating, analyzing, and sharing oncology data to foster innovation in research and patient care.

Vision

A world where evidence drives innovation in cancer care, informs policy, and improves patient outcomes.

CENTRA's goals are to:

  • Facilitate access to ASCO data assets under the terms of ASCO’s data-sharing policies;  
  • Provide statistical oversight and research design consultation for ASCO research projects, including the Targeted Agent and Profiling Utilization Registry (TAPUR™) Study;  
  • Develop resources and tools to support members’ engagement in research through the Research Community Forum;
  • Explore challenges and opportunities in today’s oncology delivery through the State of Cancer Care in America series; and  
  • Issue statements and organize meetings related to research design and clinical research efficiency. 

 

CENTRA Research Events

ASCO routinely collaborates with the U.S. Food and Drug Administration (FDA) on research-related workshops. The purpose of these events is to provide a venue for multiple stakeholders to discuss emerging and/or pressing issues in oncology research.

2021
 
Defining a Research Agenda to Address Barriers and Solutions to Oral Anticancer Agent Adherence: An ASCO-FDA Virtual Workshop – February 2 (1–4:30 PM EST) & February 3 (1–5:30 PM EST)
 
  • ASCO and the U.S. Food and Drug Administration (FDA) will host a virtual workshop, convening a diverse group of stakeholders interested oral adherence in cancer care. Each workshop session will address a variable that impacts adherence, as well as identify potential solutions to improving adherence, gaps in knowledge, and future research questions. In particular, workshop sessions will explore the following topics: (1) Drug Development and Clinical Pharmacology, (2) Trial Design, Adverse Event Reporting, and Translation of Information, (3) Social Determinants of Adherence, and (4) Adherence in Special Populations: Adolescent and Young Adults and Older Adults.

2020

FDA-ASCO Clinical Outcome Assessments in Cancer Clinical Trials Workshop – July 17, 2020

  • ASCO and the Food and Drug Administration (FDA) hosted a virtual workshop, once again convening regulators, payers, industry, academia, providers, and patients. The 2020 workshop focused on advancing measurement of the patient experience as it relates to tolerability in cancer clinical trials.
  • Visit the FDA website to access the workshop recording and materials.

2019

FDA-ASCO Clinical Outcomes Assessments in Cancer Clinical Trials Workshop – July 12, 2019 

  • ASCO and the Food and Drug Administration (FDA) convened international regulators, payers, industry, academia, providers, and patients for a workshop aimed at advancing the science of clinical outcome assessments. The goal of this meeting was to explore the use of physical function as an outcome measure and advance the standardization of data collection, COA tools, endpoints, analysis, and visualization of physical function in oncology for regulatory decision-making.
  • Visit the FDA website to access the workshop recording and materials.

FDA-ASCO-Friends of Cancer Research Workshop: Development of Tissue-Agnostic, Biomarker-Based Indications – April 26, 2019 

  • This workshop explored concepts in research and development (R&D) that could help the research community and regulators understand how to optimize product development and patient access to safe and effective biomarker-driven therapies that have clinical use across a variety of cancer types. 

2018

FDA-ASCO Clinical Outcomes Assessments in Cancer Clinical Trials Workshop – June 22, 2018

  • This workshop addressed topics beyond the standard assessment endpoints of survival and tumor measurements, including improving methods to quantify how patients experience symptoms and the impact on physical functional outcomes and health-related quality of life.

2017

FDA-ASCO Public Workshop: Geriatric Oncology – November 6, 2017

Assessment of Cardiovascular Toxicities in Immuno-oncology Trials - December 1, 2017

  • The focus of the workshop was to identify best practices to assess cardiovascular and metabolic toxicities in patients receiving cancer immunotherapies.

Random Quote

"ASCO is leading the move to a new data-driven era of discovery in clinical oncology."
Peter Paul Yu, MD, FACP, FASCO
ASCO President, 2014-15